Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

LOS ANGELES, July 06, 2022 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 25, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ:SPRO ) securities between October 28, 2021 and May 2, 2022 , inclusive (the "Class Period"). If you suffered a loss on your Spero investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/spero-therapeutics-inc/ . You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On October 28, 2021, Spero announced that it had submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for its urinary tract infection treatments, tebipenem HBr. On March 31, 2022, Spero released its fourth quarter and full year 2021 financial results, disclosing that the FDA had notified the Company that it had "identified deficiencies" in the NDA "that preclude discussion of labeling and post-marketing requirements/commitments." On this news, ... Full story available on Benzinga.com